LRRK2 (Leucine-Rich Repeat Kinase 2) Parkinson's Disease Fingerprint
NCT07681219
Basal Ganglia Diseases, Brain Diseases
View Trial DetailsNCT Number: NCT07201610
This study will investigate new, non-invasive methods to help diagnose Parkinson's disease. Researchers will use advanced eye imaging (hyperspectral retinal photography and OCT), computerized memory and thinking tests, and voice analysis to identify patterns linked to Parkinson's. The goal is to improve early and accurate diagnosis of Parkinson's disease without the need for spinal taps or invasive tests.
Trial opening soon.
Get Notified60 year–80 year
All sexes
Observational
This study aims to improve how Parkinson's disease is diagnosed by testing new, non-invasive techniques that do not require spinal taps or other invasive procedures. Researchers are investigating whether changes in the eye's retina, detected with hyperspectral imaging and optical coherence tomography (OCT), can help pinpoint Parkinson's disease. These methods use special photographs and scans, similar to those performed at an eye clinic or optometrist, to analyze patterns linked to nerve cells and blood vessels in the retina.
Additionally, participants will take computerized tests to measure memory, attention, and thinking skills. Since Parkinson's disease can also affect speech, the study will analyze voice recordings for specific changes that are common in the disease, such as reduced volume and strength. By combining information from eye images, cognitive tests, and voice analysis, the project hopes to develop a faster and more accurate way to diagnose Parkinson's disease at an earlier stage.
The study is open to both people with Parkinson's disease and healthy volunteers, and the new diagnostic tools being tested could make future diagnosis simpler, more comfortable, and accessible to a wider population
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
for Parkinson's group:
Inclusion criteria
for control group:
Exclusion criteria
Definition of healthy:
Time frame: Through study completion, an average of 6 months
To assess the performance (AUC) of an optimized diagnostic model that combines HSI, OCT, and angio-OCT data with computerized cognitive testing and voice analysis for identifying Parkinson's disease
Time frame: Through study completion, an average of 6 months
To evaluate the performance (AUC) of a diagnostic model that combines hyperspectral retinal imaging (HSI), and optimally selected data from OCT and angio-OCT, for classifying patients with Parkinson's disease
Time frame: Through study completion, an average of 6 months
Diagnostic performance for each diagnostic modality, HSI, OCT, voice and cognitive testing
Time frame: Through study completion, an average of 6 months
Correlation measures for each retinal modality with cognition and functional scale for Parkinson's disease
Contact information is provided by the study sponsor or research team.
Blekinge Institute of Technology
Other
Non-invasive Diagnosis of Parkinson's Disease Using Hyperspectral Retinal Imaging, Optical Coherence Tomography, Computerized Cognitive Testing, and Voice Analysis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07681219
Basal Ganglia Diseases, Brain Diseases
View Trial DetailsNCT07369310
Basal Ganglia Diseases, Brain Diseases
Barcelona, Spain
View Trial DetailsNCT07141719
Basal Ganglia Diseases, Brain Diseases
Kiel, Schleswig-Holstein, Germany
View Trial DetailsNCT06999330
Anxiety, Anxiety Disorders
Saint Paul, Minnesota, United States
View Trial Details